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ABSTRACT 
 
 
The first line symptomatic treatment for AD is ChEIs. Study on factors that 
associated with intolerability towards ChEIs in elderly with dementia among Malaysian 
is still lacking. Study aimed to identify factors associated with intolerability towards 
ChEIs and to introduce genotyping to identify genetic factor that may influence 
intolerability. Factors analysis were based on retrospective record-review and 
prospective cross-sectional laboratory analysis for genotyping among patients in 
GMOC, HKL. Patients’ aged 60 years and above with the first exposure with ChEIs 
were included. Intolerability define as stopping the drug or reducing the dosage because 
of adverse effects. The intolerability found to be 42.9 %. Sociodemographic factors was 
not a predictor of intolerability. Drug and SE is the main factors that affecting 
intolerability. FACED study found patients who were intolerant were at 53 times chance 
having intolerability at initiation dose regime (OR=53.48, 95 % CI 6.717-425.883, 
p<0.001), use of concomitant CYP3A4 substrate having 11 times chances of 
intolerability (OR=11.05, 95 % CI 1.256-97.146, p=0.030) and patient who developed 
CNS SE were 7 times risk develop intolerability (OR=7.14, 95 % CI 1.672-30.504, 
p=0.008). For clinical factor, by increasing 1 mmol/L of serum FBG, the chances of 
intolerability can be reduce by 70 % (OR=0.30, 95 % CI 0.126-0.700, p=0.050). 
Genotyping identified the most frequent genetic polymorphism were allele *4 (88.8 %), 
*10 (55.6 %) and *14 (11.1 %). Four intolerants’ are IM but one patient is an EM and 
does having risk factor as identified earlier and taking CYP2D6 inhibitor agent. This 
study serve as a new data for our local population. It provide an additional knowledge 
for pharmacist to play a role in planning for modification of therapy to improve 
management in dementia patient who requires ChEIs. 
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